Survodutide
Also referenced as: BI 456906
A dual glucagon and GLP-1 receptor agonist studied in obesity and MASH.
- Evidence grade
- BModerate Human Evidence
Moderate Human Evidence
- Regulatory status
- Clinical Trials
Investigational; not FDA-approved for the uses discussed.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A dual glucagon and GLP-1 receptor agonist studied in obesity and MASH.
Investigational; not FDA-approved for the uses discussed.
Adherence-based estimates differ from treatment-regimen estimates, and weight reduction does not establish cardiovascular-event benefit.
Why It's Being Studied
- Obesity research
- MASH research
- Dual receptor agonism
Mechanism of Action
It combines GLP-1 satiety signalling with glucagon-pathway metabolic effects.
It combines GLP-1 satiety signalling with glucagon-pathway metabolic effects. Adherence-based estimates differ from treatment-regimen estimates, and weight reduction does not establish cardiovascular-event benefit.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Obesity research
- MASH research
- Dual receptor agonism
- Subcutaneous clinical research
Evidence Summary
The sponsor reported positive phase 3 SYNCHRONIZE weight-loss findings in 2026, alongside liver-disease development.
Higher tiers carry more weight. Filled tiers have evidence for Survodutide; tap to read it.
- The sponsor reported positive phase 3 SYNCHRONIZE weight-loss findings in 2026, alongside liver-disease development.
1 cited sources.
- Regulatory document1
Human clinical evidence
- The sponsor reported positive phase 3 SYNCHRONIZE weight-loss findings in 2026, alongside liver-disease development.
Reported Adverse Events in Research
- Gastrointestinal tolerability and discontinuations are important to interpreting results.
Limitations of Current Evidence
- Adherence-based estimates differ from treatment-regimen estimates, and weight reduction does not establish cardiovascular-event benefit.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Survodutide | Trofinetide | |
|---|---|---|
| Evidence grade | B — Moderate Human Evidence | B — Moderate Human Evidence |
| Regulatory status | Clinical Trials | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Subcutaneous clinical research | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Regulatory document
Survodutide — regulatory document